Provided by Tiger Fintech (Singapore) Pte. Ltd.

Verve Therapeutics

6.20
+0.46508.12%
Post-market: 6.17-0.0250-0.40%19:55 EDT
Volume:4.67M
Turnover:29.06M
Market Cap:552.24M
PE:-2.95
High:6.58
Open:5.85
Low:5.77
Close:5.73
Loading ...

BRIEF-Verve Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule

Reuters
·
03 Jun

Verve Therapeutics Announces New Equity Awards for Employees Under 2024 Inducement Stock Incentive Plan

Reuters
·
03 Jun

Verve Therapeutics (VERV) Gets a Buy from H.C. Wainwright

TIPRANKS
·
19 May

Analysts’ Top Healthcare Picks: ADC Therapeutics (ADCT), Verve Therapeutics (VERV)

TIPRANKS
·
15 May

William Blair Remains a Buy on Verve Therapeutics (VERV)

TIPRANKS
·
15 May

Verve Therapeutics Q1 EPS $(0.35) Versus $(0.59) YoY, Sales $32.98M

Benzinga
·
14 May

BRIEF-Verve Therapeutics Q1 Collaboration Revenue USD 32.976 Million

Reuters
·
14 May

Verve Therapeutics Reports Q1 2025 Collaboration Revenue Surge to $33M, Driven by Vertex Collaboration Termination Recognition

Reuters
·
14 May

Verve Therapeutics Q1 Collaboration Revenue USD 32.976 Million

THOMSON REUTERS
·
14 May

Verve Therapeutics Q1 Net Income USD -31.033 Million

THOMSON REUTERS
·
14 May

Press Release: Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2025 Financial Results

Dow Jones
·
14 May

Why Verve Therapeutics Zoomed 40% Higher This Week

Motley Fool
·
19 Apr

Verve Therapeutics Shares Jump After Cantor Fitzgerald Upgrade

MT Newswires Live
·
16 Apr

VERV Stock Soars on Superior Efficacy in Phase I Cholesterol Study

Zacks
·
16 Apr

Verve Therapeutics Raised to Overweight From Neutral by Cantor Fitzgerald

Dow Jones
·
15 Apr

Verve Therapeutics Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
15 Apr

Cantor Fitzgerald Upgrades Verve Therapeutics to Overweight From Neutral

MT Newswires Live
·
15 Apr

Clover Health Investments Leads The Charge In These 3 Promising Penny Stocks

Simply Wall St.
·
15 Apr

Guggenheim Reaffirms Their Buy Rating on Verve Therapeutics (VERV)

TIPRANKS
·
15 Apr

Canaccord Genuity Reaffirms Their Buy Rating on Verve Therapeutics (VERV)

TIPRANKS
·
15 Apr